Variants in> 12 genes encoding sarcomeric proteins can cause various cardiomyopathies.
The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy …

Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Acute heart failure (HF) and in particular, cardiogenic shock are associated with high
morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents …

Background Levosimendan, a novel calcium sensitiser, improves myocardial contractility
without causing an increase in myocardial oxygen demand. We compared the effects of …

ContextBecause acute decompensated heart failure causes substantial morbidity and
mortality, there is a need for agents that at least improve hemodynamics and relieve …

Troponin complex is a component of skeletal and cardiac muscle thin filaments. It consists of
three subunits—troponin I, T, and C, and it plays a crucial role in muscle activity, connecting …

The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its
specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments …

Background—We determined the short-term hemodynamic and clinical effects of
levosimendan, a novel calcium-sensitizing agent, in patients with decompensated heart …

OBJECTIVES We sought to define the therapeutic dose range of levosimendan in patients
with New York Heart Association class II-IV heart failure of ischemic origin. BACKGROUND …

Levosimendan is an inodilator indicated for the short-term treatment of acutely
decompensated severe chronic heart failure, and in situations where conventional therapy is …